Boston Partners’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $27.9M | Buy |
1,282,722
+7,397
| +0.6% | +$161K | 0.03% | 315 |
|
|
2025
Q1 | $30.6M | Sell |
1,275,325
-16,543
| -1% | -$397K | 0.04% | 275 |
|
|
2024
Q4 | $27.3M | Buy |
1,291,868
+16,601
| +1% | +$351K | 0.03% | 294 |
|
|
2024
Q3 | $25.6M | Sell |
1,275,267
-131,113
| -9% | -$2.63M | 0.03% | 303 |
|
|
2024
Q2 | $22M | Sell |
1,406,380
-100,550
| -7% | -$1.57M | 0.03% | 316 |
|
|
2024
Q1 | $23.8M | Sell |
1,506,930
-34,730
| -2% | -$548K | 0.03% | 304 |
|
|
2023
Q4 | $25.6M | Buy |
1,541,660
+1,396,930
| +965% | +$23.2M | 0.03% | 300 |
|
|
2023
Q3 | $1.69M | Hold |
144,730
| – | – | ﹤0.01% | 507 |
|
|
2023
Q2 | $1.95M | Hold |
144,730
| – | – | ﹤0.01% | 482 |
|
|
2023
Q1 | $2.4M | Hold |
144,730
| – | – | ﹤0.01% | 450 |
|
|
2022
Q4 | $2.69M | Buy |
144,730
+3,351
| +2% | +$62.3K | ﹤0.01% | 431 |
|
|
2022
Q3 | $1.81M | Buy |
141,379
+2,821
| +2% | +$36.2K | ﹤0.01% | 456 |
|
|
2022
Q2 | $971K | Buy |
138,558
+62,812
| +83% | +$440K | ﹤0.01% | 514 |
|
|
2022
Q1 | $628K | Buy |
+75,746
| New | +$628K | ﹤0.01% | 603 |
|